Which medication class is identified as warranting potassium monitoring when added to RAAS inhibitors in heart failure?

Which medication class is identified as warranting potassium monitoring when added to RAAS inhibitors in heart failure?

• A. Potassium-sparing diuretics
• B. Beta-blockers
• C. ACE inhibitors
• D. Calcium channel blockers

Answer: (A)

Potassium-sparing diuretics are the class that necessitates potassium monitoring when added to RAAS inhibitors in heart failure. These drugs prevent potassium loss in the distal nephron or block aldosterone itself, leading to higher potassium levels. RAAS inhibitors already raise potassium by reducing aldosterone-driven potassium excretion, so combining them with potassium-sparing agents markedly increases the risk of hyperkalemia. Checking potassium (and renal function) after starting or adjusting therapy helps prevent dangerous elevations. Other options don’t have this specific additive effect on potassium. Beta-blockers don’t directly affect potassium balance in this context, and calcium channel blockers don’t significantly raise potassium. ACE inhibitors are RAAS inhibitors themselves, and while potassium monitoring is important with them, the scenario described points to the potassium-sparing diuretics as the class that most clearly requires close potassium surveillance when used with RAAS inhibitors.

Potassium-sparing diuretics are the class that necessitates potassium monitoring when added to RAAS inhibitors in heart failure. These drugs prevent potassium loss in the distal nephron or block aldosterone itself, leading to higher potassium levels. RAAS inhibitors already raise potassium by reducing aldosterone-driven potassium excretion, so combining them with potassium-sparing agents markedly increases the risk of hyperkalemia. Checking potassium (and renal function) after starting or adjusting therapy helps prevent dangerous elevations.

Other options don’t have this specific additive effect on potassium. Beta-blockers don’t directly affect potassium balance in this context, and calcium channel blockers don’t significantly raise potassium. ACE inhibitors are RAAS inhibitors themselves, and while potassium monitoring is important with them, the scenario described points to the potassium-sparing diuretics as the class that most clearly requires close potassium surveillance when used with RAAS inhibitors.